Supernus Pharmaceuticals (SUPN) Projected to Announce Earnings on Tuesday

Supernus Pharmaceuticals (NASDAQ:SUPN) is anticipated to release its Q2 2026 results after the market closes on Tuesday, August 4th. Analysts expect the company to post earnings of $0.4225 per share and revenue of $205.4280 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 4:30 PM ET.

Supernus Pharmaceuticals Price Performance

Supernus Pharmaceuticals stock traded up $0.40 during trading hours on Tuesday, hitting $47.38. The company had a trading volume of 30,341 shares, compared to its average volume of 720,707. The firm has a 50-day moving average of $46.46 and a 200 day moving average of $49.23. The firm has a market cap of $2.75 billion, a PE ratio of -92.90, a PEG ratio of 0.99 and a beta of 0.54. Supernus Pharmaceuticals has a one year low of $32.83 and a one year high of $59.68.

Institutional Trading of Supernus Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Corient Private Wealth LLC acquired a new position in shares of Supernus Pharmaceuticals during the 4th quarter worth approximately $237,000. Invesco Ltd. boosted its stake in shares of Supernus Pharmaceuticals by 9.4% in the fourth quarter. Invesco Ltd. now owns 395,761 shares of the specialty pharmaceutical company’s stock valued at $19,669,000 after buying an additional 33,895 shares during the period. Mackenzie Financial Corp bought a new stake in shares of Supernus Pharmaceuticals in the fourth quarter valued at approximately $223,000. Zacks Investment Management bought a new stake in shares of Supernus Pharmaceuticals in the fourth quarter valued at approximately $1,807,000. Finally, SummitTX Capital L.P. grew its position in Supernus Pharmaceuticals by 2.7% during the fourth quarter. SummitTX Capital L.P. now owns 11,670 shares of the specialty pharmaceutical company’s stock worth $580,000 after buying an additional 303 shares in the last quarter.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on SUPN shares. Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Wednesday, June 24th. Cantor Fitzgerald lifted their price target on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an “overweight” rating in a report on Thursday, July 9th. Zacks Research upgraded Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Finally, Wall Street Zen downgraded Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Supernus Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $62.83.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained?release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended?release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended?release capsules), approved for the treatment of attention?deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.